“Retifanlimab Vs Avelumab in Patients With Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy”. Farmeconomia. Health Economics and Therapeutic Pathways, vol. 26, no. 1, Mar. 2025, https://doi.org/10.7175/fe.v26i1.1574.